5-ヒドロキシトリプタミン受容体2B治療薬市場:パイプラインレビュー(2020年上半期)

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:GDATA20MY0971)
◆英語タイトル:5-Hydroxytryptamine Receptor 2B - Pipeline Review, H1 2020
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GDATA20MY0971
◆発行日:2020年3月31日
◆調査対象地域:グローバル
◆産業分野:製薬
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥770,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,155,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[5-ヒドロキシトリプタミン受容体2B治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

5-Hydroxytryptamine Receptor 2B – Pipeline Review, H1 2020
Summary

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report 5-Hydroxytryptamine Receptor 2B – Pipeline Review, H1 2020, outlays comprehensive information on the 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) – 5-Hydroxytryptamine receptor 2B (5-HT2B) or serotonin receptor 2B is a protein encoded by the HTR2B gene. It plays a role in the regulation of behavior, including impulsive behavior. It protects cardiomyocytes against apoptosis. It plays a role in the adaptation of pulmonary arteries to chronic hypoxia and vasoconstriction. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Report covers products from therapy areas Central Nervous System, Immunology, Respiratory, Cardiovascular, Gastrointestinal, Metabolic Disorders, Musculoskeletal Disorders and Ophthalmology which include indications Drug Addiction, Attention Deficit Hyperactivity Disorder (ADHD), Idiopathic Pulmonary Fibrosis, Psychiatric Disorders, Psychosis, Schizophrenia, Systemic Sclerosis (Scleroderma), Alzheimer’s Disease, Autism, Binge Eating Disorder, Bipolar Disorder (Manic Depression), Diarrhea, Fibrosis, Insomnia, Irritable Bowel Syndrome, Major Depressive Disorder, Obesity, Obsessive-Compulsive Disorder, Ocular Hypertension, Open-Angle Glaucoma, Pulmonary Arterial Hypertension, Schizoaffective Disorder and Sedation.

Furthermore, this report also reviews key players involved in 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B)
- The report reviews 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics and enlists all their major and minor projects
- The report assesses 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

*** レポート目次(コンテンツ)***

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) – Overview
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) – Companies Involved in Therapeutics Development
AnaMar AB
Daya Drug Discoveries Inc
medac GmbH
Neurim Pharmaceuticals Ltd
RaQualia Pharma Inc
Reviva Pharmaceuticals Inc
Seropeutics LLC
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) – Drug Profiles
AM-1476 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brilaroxazine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DDD-024 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
piromelatine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00310941 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SERx-480 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize HTR2B for Fibrosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target 5HT2 for CNS Disorders and Obesity – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
terguride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) – Dormant Products
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) – Discontinued Products
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AnaMar AB, H1 2020
Pipeline by Daya Drug Discoveries Inc, H1 2020
Pipeline by medac GmbH, H1 2020
Pipeline by Neurim Pharmaceuticals Ltd, H1 2020
Pipeline by RaQualia Pharma Inc, H1 2020
Pipeline by Reviva Pharmaceuticals Inc, H1 2020
Pipeline by Seropeutics LLC, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020

*** 掲載企業 ***

AnaMar AB
Daya Drug Discoveries Inc
medac GmbH
Neurim Pharmaceuticals Ltd
RaQualia Pharma Inc
Reviva Pharmaceuticals Inc
Seropeutics LLC

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GDATA20MY0971 )"5-ヒドロキシトリプタミン受容体2B治療薬市場:パイプラインレビュー(2020年上半期)" (英文:5-Hydroxytryptamine Receptor 2B - Pipeline Review, H1 2020)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。